Home › Research › Costs and economics
Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review
Jiang X, Lv G, Xiong X, Yuan J, Kevin Lu Z. Journal of Alzheimer's Disease, 2026-03-16
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
BackgroundSeveral monoclonal antibodies designed to slow cognitive and functional decline in individuals with early Alzheimer's disease (AD) have been recently approved. However, a comprehensive evaluation of the cost-effectiveness of all FDA-approved neurotherapeutic agents for AD remains lacking.ObjectiveThis study aimed to systematically review and analyze the incremental costs and effectiveness of currently available FDA-approved neurotherapeutic agents for AD to provide consolidated evidence on their economic value.MethodsA systematic review was conducted across PubMed, Embase, Cochrane CENTRAL, and Web of Science, adhering to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and PRISMA guidelines.ResultsTwenty-three articles were included. Most studies (74%) used a Markov model. Nearly half (48%) of studies were analyzed from both healthcare system and societal perspectives. Industry-funded studies made up 43%, while 39% were funded by non-profits, and 17% received no funding. Quality-adjusted life year (QALY) was the most common effectiveness measure (91%). At a willingness-to-pay (WTP) threshold of $100,000/QALY, all studies found memantine cost-effective, and more than half reported cost-effectiveness for donepezil, rivastigmine, and galantamine. Aducanumab, lecanemab, and donanemab were not cost-effective in any study. Under the WTP threshold of $150,000/QALY, value-based prices for aducanumab, lecanemab, and donanemab were estimated below $5,960, $15,700, and $33,700, respectively.ConclusionsTraditional symptom-targeting drugs were consistently cost-effective, whereas anti-amyloid therapies were not. Future independent cost-effectiveness analyses would benefit from head-to-head comparisons using real-world data and greater attention to disparities in dementia research.
What this study adds
Evidence grade: Moderate
This is a pooled review. At a willingness-to-pay threshold of $100,000 per QALY, all included studies found memantine cost-effective and more than half reported cost-effectiveness for donepezil, rivastigmine and galantamine, while aducanumab, lecanemab and donanemab were not cost-effective in any study. These conclusions come from economic models, not from new trials of whether these drugs work.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jiang, X., Lv, G., Xiong, X., Yuan, J., & Kevin Lu, Z. (2026). Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review. Journal of Alzheimer's Disease. https://doi.org/10.1177/13872877261430376
Vancouver
Jiang X, Lv G, Xiong X, Yuan J, Kevin Lu Z. Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review. Journal of Alzheimer's Disease. 2026. doi:10.1177/13872877261430376. PMID: 41837605.
BibTeX
@article{jiang2026-41837605,
author = {Jiang, X. and Lv, G. and Xiong, X. and Yuan, J. and Kevin Lu, Z.},
title = {{Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review}},
journal = {Journal of Alzheimer's Disease},
year = {2026},
doi = {10.1177/13872877261430376},
pmid = {41837605},
url = {https://doi.org/10.1177/13872877261430376}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Quality-adjusted life year (QALY) was the most common effectiveness measure (91%).
- At a willingness-to-pay (WTP) threshold of $100,000/QALY, all studies found memantine cost-effective, and more than half reported cost-effectiveness for donepezil, rivastigmine, and galantamine.
- Aducanumab, lecanemab, and donanemab were not cost-effective in any study.
- Under the WTP threshold of $150,000/QALY, value-based prices for aducanumab, lecanemab, and donanemab were estimated below $5,960, $15,700, and $33,700, respectively.ConclusionsTraditional symptom-targeting drugs were consistently cost-effective, whereas anti-amyloid therapies were not.
- Future independent cost-effectiveness analyses would benefit from head-to-head comparisons using real-world data and greater attention to disparities in dementia research.
Why it matters
At a willingness-to-pay threshold of $100,000 per QALY, all included studies found memantine cost-effective and more than half reported cost-effectiveness for donepezil, rivastigmine and galantamine, while aducanumab, lecanemab and donanemab were not cost-effective in any study. These conclusions come from economic models, not from new trials of whether these drugs work.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designsystematic-review
- Effect sizeAnti-amyloid antibodies not cost-effective in any of 23 studies; value-based prices below $5,960-$33,700 per year at $150,000/QALY
- Evidence strengthModerate
How this study scored 49/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size and studied in people because the record does not state it. We have no data on senior author's track record and free to read, so those were left out: it earned 46 of the 94 points we could judge it on, which is 49 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's Disease) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Z. Kevin Lu holds only 9 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 1 / 3 | University of Cincinnati: institution h-index 918 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41837605) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 46 / 94 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 46 of the 94 points we could judge it on is 49 out of 100. |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Costs and economics from nearby years
Also in Costs and economics
21 studies in the library are filed under Costs and economics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Costs and economics hub.